Bo Wiinberg
About Bo Wiinberg
Bo Wiinberg serves as the Chief Business Development Officer at the Novo Nordisk Foundation Cellerator, where he focuses on advancing cell therapies and supporting their development. He has held various leadership roles at Novo Nordisk and has extensive experience in research, strategy, and innovation in the pharmaceutical and biotechnology sectors.
Current Role at Novo Nordisk Foundation Cellerator
Bo Wiinberg serves as the Chief Business Development Officer at the Novo Nordisk Foundation Cellerator, a position he has held since 2024. In this role, he contributes to the Cellerator's mission of advancing cell therapies derived from various stem cell types. His responsibilities include overseeing the development of services ranging from process development to GMP manufacturing, product release, and regulatory support. Under his leadership, the Cellerator aims to address the need for facilities capable of producing cell therapy products in large, consistent quantities, with operations expected to commence in 2027.
Previous Experience at Novo Nordisk
Prior to his current role, Bo Wiinberg held several positions at Novo Nordisk. He worked as Head of Strategy, Operations, Portfolio, Innovation, and Communication in Stem Cell R&D from 2020 to 2021. He also served as Head of Translational Haemophilia Pharmacology from 2014 to 2016 and as Head of Haemophilia Biology from 2016 to 2018. Additionally, he was the R&D Strategy Director focusing on Pharma Leadership, Business Development, Innovation, and Transformation from 2018 to 2020. His extensive experience at Novo Nordisk spans various aspects of research and development in the biopharmaceutical sector.
Academic Background and Qualifications
Bo Wiinberg has a strong academic foundation in veterinary medicine and related fields. He studied at Den Kgl. Veterinær- og Landbohøjskole, earning a Doctor of Veterinary Medicine (DVM) from 1995 to 2003. He also completed his PhD in Inflammation & Hemostasis at the University of Copenhagen from 2004 to 2007. His academic pursuits included a postdoctoral fellowship at the University of Copenhagen and MSc studies at Cornell University. Additionally, he has engaged in business education, achieving an Executive MBA from IMD in 2021.
Entrepreneurial Experience and Advisory Roles
In addition to his roles at Novo Nordisk, Bo Wiinberg has experience in entrepreneurial and advisory capacities. He served as an Entrepreneur in Residence at the BioInnovation Institute from 2022 to 2023. He also worked as a Senior Advisor at Biobridge Partners during the same period. These roles allowed him to leverage his expertise in business development and innovation within the biotechnology sector.
Contributions to Cell Therapy Development
Bo Wiinberg plays a significant role in the Novo Nordisk Foundation Cellerator's efforts to support the development of cell therapies. He is involved in philanthropic activities aimed at serving clients from academia, biotech, and the pharmaceutical industry on both national and international levels. His contributions are instrumental in establishing a state-of-the-art laboratory facility that focuses on advancing cell therapies and ensuring consistent manufacturing for early clinical trials.